32 results
10-Q
2020 Q3
GLTO
Galecto Inc
11 Dec 20
Quarterly report
7:30am
;
costs to defend the related litigation;
diversion of management’s time and our resources;
substantial monetary awards to trial participants … become subject to investigations by Nasdaq, the SEC, and other regulatory
authorities, and become subject to litigation from investors and stockholders
UPLOAD
GLTO
Galecto Inc
29 Sep 20
Letter from SEC
12:00am
here to the Private Securities Litigation
Reform Act of 1995.
Please note that the PSLRA safe harbor provisions do not apply to
initial … Litigation Reform Act or make clear that the
safe harbor does not
apply to this offering.
Use of Proceeds, page 78
5. We note your
10-K
2020 FY
GLTO
Galecto Inc
29 Mar 21
Annual report
6:03am
breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject … to fines and penalties, litigation, and reputational harm in connection with our European activities. Further, the U.K.’s decision to leave the EU, often
424B4
hza dzc5x
30 Oct 20
Prospectus supplement with pricing info
4:31pm
DRS
wxx4 jwdgse04uk
2 Sep 20
Draft registration statement
12:00am
S-1/A
8yribt n07m6muz5y8
22 Oct 20
IPO registration (amended)
6:13am
S-1
ph4bhdsh
7 Oct 20
IPO registration
5:01pm
S-1/A
EX-1.1
t38itchviwu
22 Oct 20
IPO registration (amended)
6:13am
8-K
EX-99.1
3um7j0mu
26 Sep 23
Galecto Announces Plans to Explore Strategic Alternatives
4:05pm
8-K
EX-99.1
rx8jok
23 Nov 20
Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors
4:15pm
8-K
EX-99.1
n6utbm2x0h2nz4t
8 Jan 21
Galecto Appoints Anne Prener to its Board of Directors
8:15am
8-K
EX-99.1
yssr5l56cxxg3m7rit
15 Mar 21
Regulation FD Disclosure
7:52am
8-K
EX-99.1
liko2ra
5 Jan 21
Results of Operations and Financial Condition
4:31pm
8-K
EX-99.1
cim4b yvegu5ba
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
8-K
EX-99.1
jthy nn6qf4g5hrvv
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
EX-99.1
bo18e 3akvk5e3656q
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
8-K
EX-99.1
l594405
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
xnt zmwnxtudkb3x87
26 Sep 23
Galecto Announces Plans to Explore Strategic Alternatives
4:05pm